Biotech Values

[DewDiligence]

Genmab, GSK’s Arzerra gets CHMP approval in CLL:

http://finance.yahoo.com/news/ArzerraTM-Ofatumumab-Receives-pz-2817847237.html?x=0&.v=1

The CHMP approval is for the second-line setting, the same indication for which Arzerra was approved by the FDA in Oct 2009 (#msg-42935958) under the Accelerated Approval program.

The Arzerra program also includes first-line CLL and autoimmune diseases such as RA—see the prologue of #msg-40412567 for details.

GSK licensed Arzerra (a/k/a/ ofatumumab; f/k/a/ HuMax-CD20) in 2006 in one of the largest biotech deals ever for any company (#msg-15652707).